KCAS Bioanalytical and Biomarker Services Announces Growth to Scientific Leadership Team
25 Apr 2023
Executive Change
Preview
Source: Business Wire
'The industry-leading team and equipment at FlowMetric will continue to push the boundaries of rapidly developing technology in this space to ensure that our clients have access to the thought leadership and technology they need to advance their R&D to bring their products to market.'
Preview
Source: Business Wire
OLATHE, Kan.--(BUSINESS WIRE)--KCAS Bioanalytical and Biomarker Services, along with our recently acquired FlowMetric and Active Biomarkers, is pleased to announce the expansion of our leadership team, adding Brian Wile, Ph.D. to head the efforts at our FlowMetric facility, Adam Cotty, Ph.D. promoted to Sr. Director, Cellular and Flow Cytometry Services, and Cheikh Kane, Ph.D. promoted to Executive Director, Biopharma Services.
Brian Wile, Ph.D., has joined the FlowMetric team, a KCAS company, to lead FlowMetric at Spring House Industrial Park located in Spring House, PA. and Milan, Italy. Brian has a Ph.D. in Biomedical Engineering from Georgia Tech and Emory in Atlanta, GA. Brian began his CRO career in the Flow Cytometry department at Q2 Solutions. He oversaw a rapid expansion as he led the transfer of over 100 client assays and tripled revenue in 2 years. He also managed the technical services team at Q2, establishing processes to bridge multiple LIMs systems as part of a merger process and developed streamlined reporting methods for high-complexity assays. Brian has experience at Eurofins as the Global Head of Scientific Affairs, responsible for assigning testing to trials based on protocol and regulatory requirements and establishing a new service line to allow same day PBMC isolation. Most recently, Brian held a role at Teknova as the Director of Scientific Affairs, working with clients to understand bioprocess pain points and obtaining customer insight for use in new product development.
"I'm excited to join the FlowMetric and KCAS teams at a pivotal time in the history of drug development. As we learn more about the human immune system and its interactions with oncology, autoimmune, and infectious disease treatments, high-parameter flow cytometry assays are becoming increasingly important to understand patient responses to clinical interventions and develop deeper pharmacodynamic insights," says Brian.
Adam Cotty, Ph.D., was promoted to Sr. Director, Cellular & Flow Cytometry Services, January 2023. Adam joined the FlowMetric team in 2017 as Assistant Director of Client Relations. Adam has over 19 years of experience in research, including Flow Cytometry and project management. Adam earned his Ph.D. in Cell and Molecular Biology from the University of the Sciences in Philadelphia, focusing on a novel application of chimeric antigen receptor technology.
As Senior Director, Adam is responsible for managing the operations of the Cellular and Flow Cytometry Services and positioning the company for continued growth. In addition, he will continue his role as a key member of our current operations integration team and the Senior Leadership Team.
In addition to the increased leadership roles, our FlowMetric facility has moved from Doylestown, PA, to a new facility in Spring House Innovation Park, located in Lower Gwynedd, PA, just outside Philadelphia and King of Prussia, PA. The new purpose-built laboratories more than quadruple the previous capacity and support the growing need of these services for markets served by the Company. This location offers us a whole new level of size and opportunity, in terms of our current needs, as well as our future growth potential.
John Bucksath, CEO of KCAS, states, "The industry-leading team and equipment at FlowMetric will continue to push the boundaries of rapidly developing technology in this space to ensure that our clients have access to the thought leadership and technology they need to advance their R&D to bring their products to market."
Cheikh Kane, Ph.D., has been promoted to Executive Director, Biopharma Services, effective January 2023. Cheikh joined KCAS in March 2021 as Senior Director of Biopharma Services. His leadership, vision and knowledge have provided an invaluable resource to the growth of our company. Prior to joining our organization Cheikh has had a robust career in the pharmaceutical industry, where he led results-driven teams as Senior Director at Nexelis and Group Leader / Principal Scientist at Boehringer Ingelheim. Cheikh has over 18 years of experience in Bioanalytical, Biomarker and Immunogenicity. Cheikh earned his Ph.D. in Virology – Immunology from INRS-Institut Armand-Frappier in Canada.
“I look forward to this new opportunity to expand further the footprint of the bioanalytical and Biomarkers fields at KCAS. My teams will continue to deliver the cutting edge bioanalytical and biomarker solutions, to advance drug development programs by leveraging our deep knowledge and experience on complex modalities like ADC, Peptides, Fusion Proteins, ATMPs as well as new and classical antibody based modalities,” says Dr. Kane.
As Executive Director, Cheikh will be responsible for the strategic leadership and management oversight of our Biopharma Services division, positioning the company for continued growth. In addition, he will be an integral member of our global Integration strategy and will continue to be a member of the Senior Leadership Team.
About KCAS
KCAS, FlowMetric and Active Biomarkers have united as a family of companies. Our organization has expanded rapidly, emerging as a leading CRO organization employing top scientific talent and business teams to provide exceptional customer service. We are uniquely positioned to provide comprehensive GLP/GCP-compliant development services from early discovery support through product registration and beyond. Thanks to our US and European locations, we support transatlantic projects, including most global needs in bioanalytical, biomarker, cellular and molecular assay services and clinical kitting and storage management. The combined companies operate in state-of-the-art facilities located in Kansas City and Philadelphia metros, USA, Milan, Italy and Lyon, France. Our mission is to provide high-quality services to the biotech and pharmaceutical industries and to advance drug development in multiple disease areas.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.